Parvalbumin-containing GABA cells and schizophrenia: experimental model based on targeted gene delivery through adeno-associated viruses.
Behav Pharmacol 2017 Dec;28(8):630-641
aInstitute of Medical Sciences, University of Aberdeen, Aberdeen, Scotland bLaboratory of Behavioural Neuroscience, National Institute on Aging, Biomedical Research Centre, National Institutes of Health, Baltimore, Maryland, USA cInstitute of Physiology, Christian Albrechts University Kiel, Kiel, Germany.
Understanding the contribution of transmitter systems in behavioural pharmacology has a long tradition. Multiple techniques such as transmitter-specific lesions, and also localized administration of pharmacological toxins including agonists and antagonists of selected receptors have been applied. More recently, modern genetic tools have permitted cell-type selective interferences, for example by expression of light-sensitive channels followed by optogenetic stimulation in behaviourally meaningful settings or by engineered channels termed DREADDS that respond to peripherally administered drugs. Read More